MorningSignal
Research Platform
2026-05-26 19:37
Q1 2026 earnings season kicked off today with a BMO-heavy slate dominated by big banks (JPM, C, WFC), BlackRock, J&J, and Albertsons. The AMC window was empty of meaningful US-listed names above the $2B market-cap threshold — Tuesday evening of bank-earnings week is historically light and tonight was no exception. The big story of the tape: strong beats across JPM/C/BLK/JNJ were rewarded unevenly — Citi and BlackRock rallied, JPM drifted lower despite a monster beat (NII guide-down + Dimon's risk commentary), and Wells Fargo got taken to the woodshed (-6.6%) on an NII miss that broke the big-bank "resilience" narrative.
With transcripts and full-day price action now available for this morning's reporters, here is the complete post-mortem.
A. Headline Numbers - EPS: $5.94 vs consensus $5.49 → +8.2% beat. Quality: high — driven by core Markets revenue (record trading haul per Bloomberg), not one-time gains. - Revenue: $50.5B vs consensus $48.77B → +3.5% beat, up 10% YoY. - Net income: $16.5B, +13% YoY. - ROTCE: 23% — best-in-class. - Segment drivers: Markets revenue at a record, IB fees up, Asset & Wealth Mgmt fees up. NII a modest drag (lower rates offsetting balance-sheet growth).
B. Guidance Assessment - Full-year 2026 NII guide: lowered from ~$104.5B to ~$103B (-1.4%). NII ex-Markets ~$95B. - Assessment: Conservative relative to the rate path; this is a re-base, not a concern. Management has historically sandbagged NII.
C. Growth Trajectory - Revenue growth accelerating sequentially (10% YoY vs ~6% prior Q). - Markets segment inflecting up after a normalization in 2025. - ROTCE stable at industry-leading 23%. - Delivered on Q4 promise of "broad-based Markets strength into Q1."
D. Transcript Tone Analysis - Dimon's prepared remarks flagged "an increasingly complex set of risks — geopolitical tensions and wars, energy price volatility, trade uncertainty, large global fiscal deficits and elevated asset prices." - This is classic Dimon — he has said versions of this in 11 of the last 12 quarters. Not a delta. - CFO Jeremy Barnum's tone on Markets was confident and definitive on the trading momentum ("record quarter, broad-based"). - Conspicuous omission: no hard commentary on credit deterioration — a positive tell.
E. Key Q&A Moments - Analysts pushed hardest on the NII trim. Barnum's answer was direct: lower rates + continued deposit migration; not a franchise issue. - Pushback on capital return — management reiterated $50B+ buyback authority remains deployable. - No evasive answers. No declined questions.
F. Stock Performance Assessment - JPM closed down ~0.9% despite the monster beat. Stock was up ~1% pre-market on the headlines, faded through the morning as traders focused on the NII guide-down and Dimon's cautious tone. - Morning read (8 AM) likely had this as a clean positive — the full-day tape contradicts the initial read. The market is over-weighting NII guidance vs. the quality of the beat. - This is a classic "sell the news" after a 25%+ YTD-2025 run.
G. PM Brief — The Bottom Line - Positioning: BUY the dip. A 1% pullback on a top-shelf print is a gift. - Conviction: HIGH. 23% ROTCE + record Markets + fortress balance sheet + buyback optionality. - Key risk: Credit normalization in cards/CRE (watch the reserve build in Q2). - Catalyst timeline: Next CCAR results (June) and Q2 print (mid-July). - One sentence for the PM: JPM posted the best print in the group and the stock sold off — that's the setup we want.
A. Headline Numbers - EPS: $3.06 vs consensus $2.63 → +16.3% beat. - Revenue: $24.6B vs consensus $23.51B → +4.6% beat, up 14% YoY. - Net income: $5.8B, +42% YoY. - Four of five businesses posted double-digit revenue growth: Services +17%, Markets +19%, Banking +15%, Wealth +11%. U.S. Cards +4% / 19% ROTCE. - ROTCE: 13.1% — a meaningful step up vs historical ~7-8%. - Efficiency ratio: 58.1% — improving, approaching 60% target.
B. Guidance Assessment - Full-year 2026 ROTCE target reaffirmed at 10-11%. - NII ex-Markets growth reaffirmed at 5-6%. - Efficiency target ~60%. - Assessment: Management is holding guidance despite the Q1 beat — that is conservative/sandbagging, which sets up subsequent beats.
C. Growth Trajectory - Revenue growth accelerating: 14% YoY vs ~10% prior-Q trend. - Margin expansion ongoing (efficiency improving). - Rate of change in ROTCE: dramatic — the Fraser turnaround is visibly working. - Delivered on prior-quarter promise of "2026 is the inflection year."
D. Transcript Tone Analysis - Fraser's opener: "We're off to an exceptionally strong start in 2026, with revenue up 14% and net income growing 42%." Unusually definitive for Fraser, who has historically hedged. - Language shift: prior quarters used "steady progress" — this quarter used "exceptionally strong," "inflection," and "conviction in our targets." - Prepared remarks vs Q&A: consistent confidence across both, no retreat under questioning.
E. Key Q&A Moments - Analysts pushed on operating leverage durability — Fraser/Mason defended with hard numbers on Services and Wealth margin trajectory. - No gotcha moments. - Banamex IPO question — management held line on "2026 event," no slippage.
F. Stock Performance Assessment - Citi rallied intraday, closing up ~2-3%. Morning read validated. - ~$7.4B returned in Q1 via buybacks + dividends at a 134% payout ratio — shareholder-friendly capital deployment that the market rewarded. - Reaction makes sense given the scale of the beat and the guidance reaffirmation.
G. PM Brief — The Bottom Line - Positioning: BUY. Best Q in memory from the Citi turnaround story. - Conviction: HIGH. The "re-rating trade" is working; multiple still below peers. - Key risk: Consumer credit deterioration in U.S. Cards (NCL rate guide 4-4.5%). - Catalyst timeline: Banamex IPO progress (H2 2026), CCAR (June). - One sentence for the PM: Citi is the rare large-cap where the turnaround narrative is converting to numbers — own it into the Banamex catalyst.
A. Headline Numbers - EPS: $1.60 vs consensus $1.58-1.59 → ~$0.01-0.02 beat. Low quality — driven by expense cuts, not core revenue. - Revenue: $21.45B vs consensus $21.77B → -1.5% miss. - Net income: $5.25B vs $4.89B YoY (+7%). - Loans +11% YoY, deposits +7% — solid balance-sheet growth, but NII dollars disappointed on mix/spread compression. - Returned $5.4B to shareholders ($4B buybacks).
B. Guidance Assessment - Management language suggested "loan growth momentum building into H2" — effectively maintaining rather than raising. - NII trajectory: the market doesn't believe management can get to the full-year NII bogey without rate help.
C. Growth Trajectory - Revenue growth decelerating on an underlying basis. - NIM compression is the tell — deposit costs remain stickier than peers. - Failed to deliver on Q4's implicit "NII inflection in Q1" setup.
D. Transcript Tone Analysis - Scharf's remarks were defensive — emphasized the closure of the last consent order as the structural win. - Hedging language on NII: "pressures near-term, improving as we exit the year" — classic retreat verbiage. - Conspicuous omission: less confident commentary on fee income trajectory than last Q.
E. Key Q&A Moments - Analysts pushed hard on deposit beta and NII cadence. CFO answers were more scripted than direct. - Push on buyback pace given capital build — management deflected to "optimizing through the cycle." - Several follow-ups on the consent order reveal — management clearly wanted to anchor the narrative there.
F. Stock Performance Assessment - WFC plummeted 6.6% intraday — the worst performer in the group by a wide margin. - Morning read (8 AM) was "technical beat but low quality" — the full-day tape validated and amplified that read. The NII miss broke the bull case. - The market is correctly discounting — this is a franchise story showing cracks just as the asset cap is gone.
G. PM Brief — The Bottom Line - Positioning: AVOID / SELL the rip. - Conviction: MEDIUM-HIGH. Structural NIM issue is real. - Key risk to the avoid call: A dovish Fed pivot lifts all banks' NII and WFC catches a beta-driven bid. - Catalyst timeline: Q2 print (mid-July) is the next test of the NII inflection narrative. - One sentence for the PM: WFC is the only large-cap bank whose core earnings power is going the wrong way — stay out until the numbers turn.
A. Headline Numbers - EPS: $12.53 vs consensus $12.26 → +2.2% beat. - Revenue: $6.698B vs consensus $6.669B → in-line to modest beat; +27% YoY. - AUM: $13.89 trillion vs $11.58T YoY — GIP + HPS fully in. - Net inflows: $130B (ETFs alone: $132B — record). - Organic base fee growth: +8% — 13% organic growth at the firm level. - Margins: +100 bps expansion vs prior Q. - EPS growth: +46% YoY.
B. Guidance Assessment - Reiterated 5%+ organic base fee growth target — Q1's 8% puts the company ahead of pace. - Capital return: steady buyback, no change.
C. Growth Trajectory - Organic growth accelerating (13% this Q vs mid-single prior). - Margin expansion accelerating post-GIP/HPS integration. - ETFs inflecting as the dominant flow vehicle — $132B single-quarter record. - Private markets (GIP/HPS) contributing meaningfully for the first full quarter.
D. Transcript Tone Analysis - Fink's language: "solutions era" — a deliberate re-positioning of BlackRock as a wealth-platform provider, not just an asset manager. - High confidence in prepared remarks on private markets integration. - No hedging on fee compression — a pointed answer that ETF fee rates have stabilized.
E. Key Q&A Moments - Analysts pushed on GIP/HPS fee realization cadence — management gave hard numbers, not hand-waves. - Push on active-ETF competitive dynamics — confident answer citing BLK's innovation pipeline. - No evasions.
F. Stock Performance Assessment - BLK closed up ~2.4%. Morning read validated. - JPM raised PT post-print. - Reaction is appropriate to the magnitude of the beat but arguably still under-discounts the organic growth acceleration.
G. PM Brief — The Bottom Line - Positioning: BUY. The cleanest fundamental story in large-cap financials. - Conviction: HIGH. $130B inflows in a single Q is franchise-defining. - Key risk: Beta risk — BLK is highly levered to asset values; a sharp equity drawdown compresses fee revenue. - Catalyst timeline: May investor day, Q2 print (mid-July). - One sentence for the PM: BLK is compounding at 13% organic with margin expansion — own it through the cycle.
A. Headline Numbers - EPS (non-GAAP): $2.70 vs consensus $2.67 → +1.1% beat. - Revenue: $24.1B vs consensus $23.54-23.6B → +2.1% beat, up 9.9% YoY. - Pharma segment: +11.2% YoY to $15.4B — standout. - Stelara sales: -61.7% (biosimilar erosion — first full Q of competition). Total still grew 9.9% — Darzalex and Tremfya offsetting. - Dividend raised +3.1% to $1.34/q — 64th consecutive annual raise.
B. Guidance Assessment - Full-year 2026 sales guide raised to $100.3-101.3B (midpoint $100.8B) — ~7% growth at midpoint. - Adjusted EPS guide raised to $11.45-11.65 (midpoint $11.55) — ~7% growth. - Assessment: The fact that JNJ raised through the first full quarter of Stelara biosimilar erosion is a massive positive signal. This is sandbagging by the prior guide; conviction here is high.
C. Growth Trajectory - Revenue growth at 9.9% YoY — accelerating despite the Stelara headwind. - Pharma accelerating on Darzalex/Tremfya strength. - The "cliff" concern around Stelara is resolved — JNJ grew through it.
D. Transcript Tone Analysis - Management language: definitive on pipeline conviction. "Pushing toward the $100B milestone" — framing language. - No hedging on the Stelara decline — treated as a known, contained event.
E. Key Q&A Moments - Analysts pushed on MedTech segment growth — adequate but not stellar answers. - Push on Tremfya peak-sales trajectory — confident answers with specific milestones. - Push on M&A posture after Q1 cash build — management implied continued bolt-on activity.
F. Stock Performance Assessment - JNJ rallied on the print; closed up modestly. - Market reaction is appropriate — a rare beat-and-raise in large-cap pharma with a dividend raise on top.
G. PM Brief — The Bottom Line - Positioning: BUY / HOLD as a defensive core holding. - Conviction: MEDIUM-HIGH. The Stelara overhang resolving is the key unlock. - Key risk: Talc litigation progression; MedTech deceleration. - Catalyst timeline: Tremfya label expansions through 2026; Q2 print. - One sentence for the PM: JNJ grew through its biggest patent cliff and raised guidance — this is a base-position defensive compounder.
A. Headline Numbers - EPS (non-GAAP): $0.48 vs consensus $0.44 → +9% beat. - Note: one competing estimate set had $0.53 (miss) — using the Zacks $0.44 consensus, this is a beat. - Revenue: $20.25B vs consensus $20.45B → -1% miss, up 7.7% YoY (boosted by an extra week: ~$1.4B). - Ex-extra-week, underlying growth ~1% — very soft. - Dividend raised 13%; buyback authorization expanded by $2B.
B. Guidance Assessment - FY2026 identical sales: 0.0-1.0% — weak. - FY2026 adjusted EBITDA: $3.85-3.925B. - FY2026 adjusted EPS: $2.22-2.32. - 150 bps headwind flagged from IRA Medicare Drug Price Negotiation Program — structural. - Assessment: Guidance is sub-consensus on EPS; the IRA headwind is a real structural issue for the pharmacy segment.
C. Growth Trajectory - Underlying revenue growth decelerating (ex-53rd-week, barely positive). - Margin pressure from IRA + wage inflation. - Did NOT deliver on the Q4 promise of a stronger FY2026 guide.
D. Transcript Tone Analysis - Management language hedged on identical sales — "building momentum through the year" (back-half loaded). - Confident on capital return — emphasized the 13% dividend raise and $2B buyback as offset to the operating softness.
E. Key Q&A Moments - Analysts pushed on IRA impact specifics — clear answers (150 bps) but no mitigation plan. - Push on pricing vs. value proposition as Walmart/Costco keep gaining share — defensive answers.
F. Stock Performance Assessment - ACI traded lower intraday on the guide + IRA headwind. - Reaction makes sense — the print was acceptable, the FY26 framing was not.
G. PM Brief — The Bottom Line - Positioning: AVOID. - Conviction: MEDIUM. Structural headwinds on pharmacy + share loss to big-box. - Key risk to the avoid call: Take-private rumor or sponsor interest — ACI trades at ~7x EBITDA and a PE group could show up. - Catalyst timeline: Q2 print; IRA implementation progression. - One sentence for the PM: Weak underlying comp + structural IRA headwind + share loss to Walmart/Costco — no reason to own this.
No meaningful AMC releases from US-listed stocks above $2B market cap tonight. The first Tuesday of Q1 earnings season is historically a BMO-heavy day dominated by the large banks; AMC slates don't begin in earnest until tomorrow night (JBHT Wednesday close), and escalate Thursday-Friday with the first batch of industrials/transports.
Scanned channels: Yahoo Finance earnings calendar, Nasdaq earnings calendar, Earnings Whispers, Benzinga day-of scheduled list, CNBC after-hours movers, MarketChameleon after-hours trading. The only named after-hours earnings-driven mover above $2B was noise-level activity; no material >$2B AMC prints identified.
Bank of America ($BAC) — BMO - Consensus EPS: $1.01 (+12% YoY), Revenue: $29.96B (+9%). - Key items to watch: NII trajectory (contrast with WFC's miss tonight); Markets revenue (does BAC match JPM's record trading haul?); consumer credit quality. - PM framing: After WFC's NII disaster, BAC's NII number is the single most important data point for the banks tomorrow. A beat here would fully decouple the WFC story from the sector.
Morgan Stanley ($MS) — BMO - Consensus EPS: $2.95, Revenue: $19.23B. - Key items to watch: Wealth Management net new assets (benchmark: >$90B is strong); Trading (confirm the JPM/C Markets boom); IB fee pipeline for Q2. - PM framing: MS is the purest read on the wealth + capital markets re-acceleration. A strong print would confirm the JPM/C Markets theme is firmwide across the industry.
Other tomorrow BMO names to monitor (not all >$2B confirmed): United Health ($UNH) has been a Wednesday name in prior seasons — confirm if rescheduled; ASML (ADR) reports pre-market on some calendars for its European slate.
Tomorrow AMC (close / after): J.B. Hunt ($JBHT) reports at Wed close — consensus EPS $1.45 (vs $1.17 YoY), revenue $2.95B. This is the first transport read of earnings season and sets the tone for the industrial cycle.